Compare PPIH & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPIH | CGEN |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.6M | 143.1M |
| IPO Year | N/A | 2000 |
| Metric | PPIH | CGEN |
|---|---|---|
| Price | $33.00 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 92.6K | ★ 397.7K |
| Earning Date | 12-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $200,783,000.00 | $6,903,000.00 |
| Revenue This Year | $25.58 | N/A |
| Revenue Next Year | $15.38 | $231.15 |
| P/E Ratio | $19.27 | ★ N/A |
| Revenue Growth | ★ 30.74 | N/A |
| 52 Week Low | $8.81 | $1.13 |
| 52 Week High | $36.48 | $2.66 |
| Indicator | PPIH | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 72.96 | 43.67 |
| Support Level | $31.81 | $1.47 |
| Resistance Level | $33.64 | $1.55 |
| Average True Range (ATR) | 1.74 | 0.08 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 65.59 | 16.01 |
Perma-Pipe International Holdings Inc is engaged in the manufacture and sale of products in the reportable segment of Piping Systems. The company engineers, designs, manufactures, and sells specialty piping systems and leak detection systems. Specialty piping systems include insulated and jacketed district heating and cooling piping systems for efficient energy distribution from central energy plants to multiple locations, primary and secondary containment piping systems for transporting chemicals, hazardous fluids, and petroleum products, and the coating and insulation of oil and gas gathering and transmission pipelines. It operates in the United States, Canada, the Middle East, Europe, India, and other countries.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.